Last reviewed · How we verify

NCT06232928

Early Versus Late Intermaxillary Elastics in Patients With Class II Malocclusion

Completed NA Last updated 31 January 2024
What this trial tests

NA trial testing Early Class II elastics in Class II Malocclusion Division 1 in 20 participants. Completed in 10 June 2023.

Timeline
1 April 2021
Primary endpoint
23 February 2023
10 June 2023

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 April 2021
Primary completion23 February 2023
Estimated completion10 June 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

12 and older, any sex, with Class II Malocclusion Division 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial aimed to compare the effect of immediate light short Class II elastics versus conventional Class II elastics on the skeletal, dental and soft tissues in patients with Class II malocclusion. Participants with class II malocclusion divided into 2 groups; early group wore immediate light short Class II elastics and conventional group wore conventional Class II elastics on rigid stainless steel arch wires.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Early versus late intermaxillary elastics in patients with Class II malocclusion: a randomized clinical trial.
    Sayed MS, Sadek MM, Abbas NH. · · 2025 · PMID 41015414 · DOI 10.2319/113024-985.1

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing